The immunohistochemistry performed with pan-Trk antibody showed reactivity in 12/105 (11.4%) analyzed samples, but the molecular analysis showed positivity for ETV6-NTRK3 fusion in 2 cases only; therefore, we can confirm that NTRK gene fusions emerge in a only a small fraction (approximately 2%) in contradistinction to other rare paediatric neoplasms, including secretory carcinoma of the breast (15), congenital mesoblastic nephroma (16) and infantile fibrosarcoma (17) where NTRK fusion is characteristic and often disease defining. This evidence concerns the gene ETV6 and fibrosarcoma.